Korea's Hanmi And Merck Move To Sell Hanmi's Hypertension Drug In North America, China and Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
The two companies also plan for MSD to market Amosartan in six Asia-Pacific countries under the Cozzar XQ brand, possibly as early as 2011, said a Hanmi official, who added that a deal in the region would generate $500 million in sales over the next 10 years.